Physician profile
Sara Ashraf
NPI 1689069163
$17,463.03
in general payments reported to CMS, 2019-2025
44 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.54 · 2022: $608 · 2023: $7,225 · 2024: $7,828 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,380 · Food and Beverage: $6,465 · Travel and Lodging: $2,398 · Education: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,380.00 |
| Food and Beverage | $6,464.64 |
| Travel and Lodging | $2,398.18 |
| Education | $598.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11,222.43 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $679.31 | 2022-2025 | Tagrisso, Calquence, Enhertu |
| Novartis Pharmaceuticals Corporation | $570.73 | 2022-2025 | |
| Eisai INC. | $533.95 | 2022-2025 | |
| Incyte Corporation | $386.07 | 2023-2025 | Jakafi, Monjuvi, Monjuvi |
| Celgene Corporation | $383.35 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $363.53 | 2023-2025 | Xtandi, Padcev, Xospata |
| Janssen Biotech, INC. | $284.23 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $283.96 | 2023-2025 | |
| Amgen INC. | $215.48 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Exelixis INC. | $207.12 | 2023-2024 | Cabometyx |
| Seagen INC. | $206.15 | 2022 | |
| Sobi, INC | $197.87 | 2023 | |
| Aveo Pharmaceuticals, INC. | $196.19 | 2023-2025 | Fotivda |
| Merck Sharp & Dohme LLC | $157.28 | 2023-2024 | Keytruda, Welireg, Lynparza |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $140.29 | 2022-2025 | |
| Glaxosmithkline, LLC. | $134.54 | 2024 | Ojjaara |
| Daiichi Sankyo INC. | $117.56 | 2024-2025 | Enhertu |
| Medtronic, INC. | $100.15 | 2023-2024 | Osteocool Rf Ablation System |
| Pharmaessentia USA Corporation | $94.16 | 2025 | Besremi |
| Emd Serono, INC. | $84.72 | 2024-2025 | |
| Puma Biotechnology, INC. | $80.90 | 2023-2024 | Nerlynx |
| Pharmacyclics LLC, An Abbvie Company | $78.11 | 2022-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $76.49 | 2022-2023 | Libtayo |
| Gilead Sciences, INC. | $69.74 | 2024-2025 | Trodelvy |
| Abbvie INC. | $63.14 | 2024-2025 | |
| Lilly USA, LLC | $60.00 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Taiho Oncology, INC. | $55.82 | 2022-2025 | |
| Genzyme Corporation | $48.99 | 2023 | |
| Array Biopharma INC | $44.08 | 2024-2025 | Lorbrena, Xalkori, Braftovi |
| Takeda Pharmaceuticals U.S.A., INC. | $43.00 | 2023-2024 | Ninlaro, Advate |
| Karyopharm Therapeutics INC. | $42.20 | 2022-2023 | Xpovio |
| Immunocore Limited | $28.05 | 2023 | Kimmtrak |
| Jazz Pharmaceuticals INC. | $28.05 | 2023 | |
| Sumitomo Pharma America, INC. | $22.50 | 2024 | Orgovyx |
| Stemline Therapeutics INC. | $21.77 | 2024 | Orserdu |
| Cti Biopharma Corp. | $21.71 | 2022 | |
| Octapharma USA, INC. | $20.00 | 2023 | Octagam Immune Globulin (Human) |
| Myovant Sciences INC. | $19.27 | 2022 | |
| Spectrum Pharmaceuticals INC. | $19.15 | 2023 | Rolvedon |
| Shield Therapeutics INC | $17.89 | 2023 | Accrufer |
| Genentech USA, INC. | $16.03 | 2023 | Polivy, Tecentriq |
| Tersera Therapeutics LLC | $14.00 | 2023 | Zoladex |
| Morphosys, US INC. | $13.07 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.